Create Free Account

By creating account you will get access to hot stocks & personalised emails

Sonic Healthcare Ltd

Healthcare AU SHL

26.46AUD
-0.23(0.86%)

Last update at 2024-11-13T05:10:00Z

Day Range

26.0726.56
LowHigh

52 Week Range

23.0531.38
LowHigh

Fundamentals

  • Previous Close 26.69
  • Market Cap13033.36M
  • Volume1047501
  • P/E Ratio25.36
  • Dividend Yield3.90%
  • EBITDA1165.92M
  • Revenue TTM8967.40M
  • Revenue Per Share TTM18.84
  • Gross Profit TTM 2842.42M
  • Diluted EPS TTM1.07

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 931.19M 2077.20M 1828.59M 699.06M 722.26M
Minority interest -22.94700M -54.90000M 119.36M 90.64M 79.54M
Net income 684.98M 1460.57M 1315.04M 527.75M 527.75M
Selling general administrative 3868.38M 3678.97M 3423.17M 3225.13M 3200.03M
Selling and marketing expenses 217.02M 206.13M 181.71M 177.25M 158.56M
Gross profit 6889.25M 7735.69M 7137.29M 5714.47M 5188.77M
Reconciled depreciation 702.93M 675.42M 641.59M 605.87M 273.14M
Ebit 1018.21M 2157.02M 1921.11M 811.91M 808.32M
Ebitda 1721.14M 2832.44M 2562.71M 1417.78M 1081.46M
Depreciation and amortization 702.93M 675.42M 641.59M 605.87M 273.14M
Non operating income net other - - - - -
Operating income 1019.10M 2157.02M 1921.11M 811.91M 808.32M
Other operating expenses 3502.33M 4044.69M 3822.84M 3246.32M 5375.74M
Interest expense 87.03M 79.82M 92.52M 112.85M 86.06M
Tax provision 223.26M 561.74M 480.94M 157.16M 163.19M
Interest income 87.03M 79.82M 92.52M 112.85M 86.06M
Net interest income -87.02500M -79.81900M -92.51900M -112.85100M -79.42700M
Extraordinary items - - - - 0.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 223.26M 561.74M 480.94M 157.16M 163.19M
Total revenue 8168.95M 9340.15M 8754.12M 6831.84M 6184.06M
Total operating expenses 5871.04M 5578.67M 5216.18M 4902.56M 4380.45M
Cost of revenue 1279.69M 1604.46M 1616.83M 1117.37M 995.29M
Total other income expense net 10.33M 17.92M -1.32900M 43.31M -86.06300M
Discontinued operations - - - - -
Net income from continuing ops 707.93M 1515.47M 1347.66M 541.90M 559.07M
Net income applicable to common shares 684.98M 1460.57M 1315.04M 527.75M 549.73M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 14826.47M 13014.63M 12552.01M 11760.99M 12127.13M
Intangible assets - 7789.62M 7361.49M 6712.25M 6954.90M
Earning assets - - - - -
Other current assets 136.99M 113.80M 92.26M 71.64M 74.76M
Total liab 6751.35M 5092.77M 5123.84M 5256.65M 6462.73M
Total stockholder equity 7917.62M 7736.50M 7273.14M 6384.99M 5573.75M
Deferred long term liab - - - - -
Other current liab 393.18M 8.23M 21.37M 82.45M 18.19M
Common stock 4140.91M 3842.42M 3860.95M 4081.98M 4000.91M
Capital stock - 3842.42M 3860.95M 4081.98M 4000.91M
Retained earnings 3552.28M 3554.20M 3351.02M 2322.16M 1397.42M
Other liab - 460.74M 368.69M 355.33M 439.84M
Good will - 7237.43M 6852.96M 6231.85M 6486.33M
Other assets - 80.19M 259.75M 103.13M 127.29M
Cash 645.00M 797.99M 780.00M 899.83M 1230.15M
Cash and equivalents - - - - -
Total current liabilities 2322.19M 1878.34M 2084.27M 2217.94M 2070.13M
Current deferred revenue 27.49M 563.33M 702.50M 557.52M 404.99M
Net debt 3870.37M 2302.49M 2232.74M 2334.98M 3385.73M
Short term debt 661.03M 346.79M 341.86M 551.43M 663.12M
Short long term debt - - - 228.94M 364.20M
Short long term debt total 4515.37M 3100.48M 3012.74M 3234.81M 4615.88M
Other stockholder equity 3.27M -7396.62000M -7217.87000M -6404.28400M -5398.47400M
Property plant equipment - 2798.11M 2624.86M 2552.92M 2498.08M
Total current assets 2352.99M 2133.17M 2305.91M 2284.57M 2455.11M
Long term investments - 175.80M 145.22M 108.11M 91.75M
Net tangible assets - -53.11500M -88.34600M -327.26500M -1381.15100M
Short term investments - - - - -
Net receivables 1362.17M 1022.17M 1217.46M 1088.72M 986.77M
Long term debt - 1673.46M 1576.93M 1592.38M 2872.43M
Inventory 208.83M 199.20M 216.19M 224.39M 163.43M
Accounts payable 1240.49M 959.99M 1018.55M 1026.54M 983.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 221.16M 339.88M 61.17M -19.15800M 175.43M
Additional paid in capital - - - - -
Common stock total equity - - - - 4000.91M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - -0.14000M -0.14700M
Accumulated amortization - - - - -
Non currrent assets other 8.81M 45.56M 45.54M 37.86M 56.53M
Deferred long term asset charges - - - - -
Non current assets total 12473.48M 10881.46M 10246.10M 9476.42M 9672.02M
Capital lease obligations - 1427.02M 1435.80M 1413.49M 1379.25M
Long term debt total - 2753.69M 2670.88M 2683.38M 3952.76M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -580.04100M -81.20900M -20.92100M -334.91700M -1099.32900M
Change to liabilities -75.54500M 17.29M 96.42M 343.15M 29.04M
Total cashflows from investing activities -580.04100M -989.18000M -386.75000M -334.91700M -1099.32900M
Net borrowings -374.31300M -624.69200M -1582.05900M -147.40300M 117.41M
Total cash from financing activities -911.51100M -1349.29400M -1954.65800M -536.73600M 687.67M
Change to operating activities 9.74M -41.81100M 56.65M 40.07M 7.95M
Net income 684.98M 1460.57M 1315.04M 527.75M 549.73M
Change in cash 18.00M -119.83000M -330.32200M 493.50M 423.38M
Begin period cash flow 780.00M 899.83M 1230.15M 736.65M 313.27M
End period cash flow 797.99M 780.00M 899.83M 1230.15M 736.65M
Total cash from operating activities 1471.03M 2225.82M 2042.84M 1360.30M 847.31M
Issuance of capital stock 84.27M 48.81M 53.63M 23.00M 943.98M
Depreciation 632.83M 675.42M 641.59M 605.87M 273.14M
Other cashflows from investing activities -83.02800M -610.59100M 24.40M -1.82500M -712.68100M
Dividends paid -490.53000M 470.87M 426.23M 412.33M 373.72M
Change to inventory 27.46M 9.88M -65.53500M -42.84600M -12.87800M
Change to account receivables 244.26M -83.01700M -146.64400M -138.49800M 12.19M
Sale purchase of stock -130.93300M -302.54800M 53.63M 23.00M 943.98M
Other cashflows from financing activities -255.09500M -206.65300M -205.45200M 1168.11M 1363.84M
Change to netincome 42.41M 2225.82M 34.02M 5.41M -32.46500M
Capital expenditures 497.01M 378.59M 363.19M 333.09M 386.65M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 271.72M 1.99M 2.92M 5.95M 6.64M
Stock based compensation 18.45M 17.24M 12.64M 6.33M -
Other non cash items 153.22M -2135.98300M -1956.63400M -1133.61700M -822.86900M
Free cash flow 974.02M 1847.23M 1679.64M 1027.21M 460.66M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SHL
Sonic Healthcare Ltd		 -0.23 0.86% 26.46 25.36 22.32 1.45 1.65 1.90 10.21
HLS
Healius Ltd		 -0.015 0.95% 1.56 - 163.93 0.65 1.09 1.53 10.14
ACL
Australian Clinical Labs Ltd		 -0.01 0.28% 3.58 30.50 12.24 1.06 4.17 1.48 6.03
IDX
Integral Diagnostics Ltd		 -0.1 3.19% 3.03 - 20.96 1.52 2.33 2.17 151.08
MVF
Monash IVF Group Ltd		 -0.015 1.29% 1.15 - 14.99 1.80 1.91 2.30 54.34

Reports Covered

Stock Research & News

View All

Profile

Sonic Healthcare Limited offers medical diagnostic and administrative services to medical practitioners, hospitals, community health services, and patients in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, and community-based healthcare services. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.

Sonic Healthcare Ltd

Grosvenor Place, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Dr. Colin Stephen Goldschmidt F.A.I.C.D., F.R.C.P.A., M.B.B.Ch. CEO, MD & Exec. Director 1954
Mr. Christopher David Wilks B.Com., F.A.C.I.D., F.A.I.C.D. Fin. Director, CFO & Exec. Director 1958
Mr. Peter Savage Chief Bus. Officer NA
Dr. Stephen Fairy Global Chief Medical Officer NA
Mr. David Byrne Chief Exec. Officer of The Doctors Laboratory 1959
Mr. Paul J. Alexander B.Ec., C.A., F.Fin Deputy CFO & Company Sec. 1966
Mrs. G. Schottdorf Chief Exec. Officer of Schottdorf Group NA
Dr. Julian Adler Chief Exec. Officer of Sonic Imaging NA
Prashan Kulasekera Assistant Company Sec. 1972
Mr. David Byrne Chief Executive Officer of The Doctors Laboratory 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.